2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1592

Frequency and Pattern of the Uveitis in Spondyloarthritis with Biological Therapy
Abstract Number: 1636

Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohort
Abstract Number: 1166

Friend or Foe: Does Walking at Higher Intensities Increase or Decrease the Risk of Total Knee Arthroplasty over Five Years?
Abstract Number: 2733

From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associated Vasculitis
Abstract Number: 1826

From Cancer to Autoimmunity : A New Model of Rheumatoid Arthritis Emerging from a Constitutional Genetic Approach Used in Low Penetrance Cancers
Abstract Number: 986

Fucosylated Tumor Necrosis Factor α Is Expressed in Rheumatoid Arthritis Synovial Tissues and Is Involved in Monocyte Adhesion
Abstract Number: 1336

Functional, Radiographic and Serologic Correlates of Anti-SSA52 Kd – Associated Interstitial Lung Disease
Abstract Number: 1760

Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis
Abstract Number: 2818

Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Abstract Number: 2040

Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.
Abstract Number: 270

Gaps in Knowledge about the Ontario Trillium Drug Program
Abstract Number: 2858

Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Abstract Number: 790

Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
Abstract Number: 133

GBR830, a True OX40 Antagonist Antibody with Potent Suppressive Effects on T Cell-Mediated Pathological Responses
Abstract Number: 276

Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].